Status message

Not the entire site translated, but only to "Journal"

Algorithm for Biological Therapy of Depression in Bipolar Affective Disorder

E.G. Kostyukova, S.N. Mosolov
Moscow research Institute of Psychiatry-Branch of the V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation, Moscow, Russia
Summary. The article presents an updated algorithm for the treatment of depression in bipolar affective disorder. The relevance of this work is due not only to the high prevalence and powerful maladaptive effect of the disease, but also to the emergence of new drugs and the formation of new approaches to therapy. First of all, this concerns limiting the use of antidepressants in the treatment of depression in bipolar disorder and expanding the use of second-generation antipsychotics.
The algorithm is based on the analysis of literature data, taking into account the latest evidence-based studies and meta-analyses and expert opinions. The choice of medicines for various stages of therapy is determined by the degree of evidence available about them.
Contacts: Kostyukova Еlena, ekostukova@gmail.com 
https://orcid.org/0000-0002-9830-1412
Mosolov Sergey, profmosolov@mail.ru 
https://orcid.org/0000-0002-5749-3964
Citation: Kostyukova E.G., Mosolov S.N. Algorithm for Biological Therapy of Depression in Bipolar Affective Disorder // Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. – 2020. – No. 4. – P. 36–43. – DOI: 10.21265/PSYPH.2020.97.57.005 [in Russian] 
Conflict of interest: the authors declare no conflict of interest
 

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Hwu H.G., Yeh E.K., Chang L.Y. Prevalence of psychiatric disorders in Taiwan defined by the Chinese Diagnostic Interview Schedule // Acta Psychiatr Scand. – 1989. – Vol. 79. – P. 136–147.
2.    Wittchen H.U., Essau C.A., von Zerssen D., Krieg J.C., Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study // Eur Arch Psychiatry Clin Neurosci. – 1992. – Vol. 241. – P. 247–258.
3.    Hirschfeld R.M.A., Calabrese J.R., Weissman M. et al. Lifetime prevalence of bipolar I and II disorders in the United States [abstract] // Presented at the 155th American Psychiatric Association Annual Meeting. – May 18–23, 2002, Philadelphia, PA, USA.
4.    Kessler R.C., McGonagle K.A., Zhao S. et al. Lifetime and 12-month prevalence of DMS-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey // Arch Gen Psychiatry. – 1994. – Vol. 51. – P. 18–19.
5.    Grande I., Berk M., Birmaher B. et al. Bipolar disorder // Lancet. – 2016. – Vol. 387. – P. 1561–1572.
6.    Judd L.L., Akiskal H.S. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder // Curr Psychiatry Rep. – 2003. – Vol. 5, No. 6. – Р. 417–418. 
7.    Judd L.L., Akiskal H.S., Schettler P.J. et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder // Arch Gen Psychiatry. – 2002. – Vol. 59 (6). – P. 530–537. 
8.    Post R.M., Denicoff K.D., Leverich G.S. et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method // J Clin Psychiatry. – 2003. – Vol. 64 (6). – P. 680–690. 
9.    Judd L.L., Schettler P.J., Akiskal H.S. et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders // Int J Neuropsychopharmacol. – 2003. – Vol. 6. – Р. 127–137. 
10.    Novis F., Cirillo P., Da Silva R.A. et al. The progression of 102 Brazilian patients with bipolar disorder: outcome of first 12 months of prospective follow-up // Trends Psychiatry Psychother. – 2014. – Vol. 36. – P. 16–22.
11.    Baldessarini R.J., Salvatore P., Khalsa H.-M.K. et al. Morbidity in 303 first-episode bipolar I disorder patients // Bipolar Disord. – 2010. – Vol. 12. – P. 264–270.
12.    Merikangas K.R., Jin R., He J.P. et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative // Arch Gen Psychiatry. – 2011. – Vol. 68 (3). – P. 241–251.
13.    Post R.M. Treatment of bipolar depression // Psychiatr Clin North Am. – 2016. – Vol. 39. – P. 11–33.
14.    Hawton K., Sutton L., Haw C. et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors // J Clin Psychiatry. – 2005. – Vol. 66. – P. 693–704.
15.    Latalova K., Kamaradova D., Prasko J. Suicide in bipolar disorder: a review // Psychiatry Danub. – 2014. – Vol. 26. – P. 108–114.
16.    Isometsä E.T., Henriksson M.M., Aro H.M. et al. Suicide in bipolar disorder in Finland // Am J Psychiatry. – 1994. – Vol. 151. – P. 1020–1024.
17.    Beyer J.L. The use of antidepressants in bipolar depression // Handb Exp Pharmacol. – 2019. – Vol. 250. – P. 415–442.
18.    Möller H.J., Grunze H., Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? // Eur Arch Psychiatry Clin Neurosci. – 2006. – Vol. 256. – P. 1–16.
19.    Fountoulakis K.N. An update of evidence-based treatment of bipolar depression: where do we stand? // Curr Opin Psychiatry. – 2010. – Vol. 23. – P. 19–24.
20.    Viktorin A., Lichtenstein P., Thase M.E. et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer // Am J Psychiatry. – 2014. – Vol. 171. – P. 1067–1073.
21.    Gitlin M.J. Antidepressants in bipolar depression: an enduring controversy // Int J Bipolar Disord. – 2018. – Vol. 6. – P. 25.
22.    Yatham L., Kennedy S., Parikh S. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder // Bipolar Disorders. – 2018. – P. 1–74.
23.    Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Möller H.J. et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression // World J Biol Psychiatry. – 2010. – No. 11. – Р. 81–109.
24.    Hamilton M. A rating scale for depression. Journal of Neurology // Neurosurgery and Psychiatry. – 1960. – Vol. 23. – P. 56–62.
25.    Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change // British Journal of Psychiatry. –1979. – Vol. 134 (4). – P. 382–389. – DOI: 10.1192/bjp.134.4.382
26.    Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials // Br J Psychiatry. – 2009. – Vol. 194. – P. 4–9.
27.    Ushkalova A.V., Kostyukova E.G., Mosolov S.N. Problemy diagnostiki i terapii bipolyarnoi depressii: ot dokazatel’nykh nauchnykh issledovanii k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel’naya meditsina — klinicheskoi praktike / pod. red. S.N. Mosolova. – M.: Sotsial’no-politicheskaya mysl’, 2012. – S. 491–529.
28.    Smith L.A., Cornelius V.R., Azorin J.M., Perugi G., Vieta E., Young A.H. et al. Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis // J Affect Disord. – 2010. – Vol. 122. – Р. 1–9.
29.    Davis L.L., Bartolucci A., Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study // J Affect Disord. – 2005. – Vol. 85, No. 3. – Р. 259–660.
30.    Calabrese P. et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression // J Clin Psychiatry. – 1999. – No. 60. – Р. 79–88.
31.    Mosolov S.N., Kostyukova E.G., Kuzavkova M.V. Bipolyarnoe affektivnoe rasstroistvo: diagnostika i terapiya / pod red. S.N. Mosolova. – M.: MEDpress-inform, 2008. – S. 15.
32.    Ballenger J.C. The clinical use of carbamazepine in affective disorders // J Clin Psychiatry. – 1988. – No. 49. – Р. 13–21.
33.    Post R.M. et al. Alternative approaches to refractory depression in bipolar illness // Depress Anxiety. – 1997. – No. 5. – Р. 175–189.
34.    Mosolov S.N., Kostyukova E.G. Bipolyarnoe affektivnoe rasstroistvo // Natsional’noe rukovodstvo. Psikhiatriya / pod red. Yu.A. Aleksandrovskogo, N.G. Neznanova. – M.: Geotar Media.– 2018. – S. 704–799.
35.    Miskowiak K.W., Carvalho A.F., Vieta E., Kessing L.V. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations // Eur Neuropsychopharmacol. – 2016. – Vol. 26. – P. 1541–1561.
36.    Yatham L.N., Mackala S., Basivireddy J., et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomized, open-label, pilot study // Lancet Psychiatry. – 2017. No. 4. – P. 208–217.
37.    Reinares M., Sanchez-Moreno J., Fountoulakis K.N. Psychosocial interventions in bipolar disorder: what, for whom, and when // J Affect Disord. – 2014. – Vol. 156. – P. 46–55.
38.    Viktorin A., Lichtenstein P., Thase M.E. et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer // Am J Psychiatry. – 2014. – Vol. 171. – P. 1067–1073. 
39.    McElroy S.L., Weisler R.H., Chang W. et al. A double-blind, placebo- controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) // J Clin Psychiatry. – 2010. – Vol. 71. – P. 163–174.
40.    Peet M. Induction of mania with selective serotonin reuptake inhibi ors and tricyclic antidepressants // Br J Psychiatry. – 1994. – Vol. 164. – P. 549–545.
41.    Post R.M., Altshuler L.L., Leverich G.S. et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline // Br J Psychiatry. – 2006. – Vol. 189. – P. 124–131.
42.    Himmelhoch J.M., Fuchs C.Z., Symons B.J. A double-blind-study of tranylcypromine treatment of major anergic depression // J Nerv MentDis. – 1982. – Vol. 170. – P. 628–634.
43.    Himmelhoch J.M., Thase M.E., Mallinger A.G., Houck P. Tranylcypromine versus imipramine in anergic bipolar depression // Am J Psychiatry. – 1991. – Vol. 148. – P. 910–916.
44.    Gijsman H.J. et al. Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. // Am J Psychiatry. – 2004. – No. 161. – Р. 1537–1547.
45.    Selle V., Schalkwijk S., Vázquez G.H., Baldessarini R.J. Treatments for acute bipolar depression: meta-analyses of 
placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics // Pharmacopsychiatry. – 2014. – Vol. 47. – P. 43–52. 
46.    Maneeton N., Maneeton B., Srisurapanont M., Martin S.D. Quetiapine monotherapy in acute phase for major depressive disorder: a meta- analysis of randomized, placebo-controlled trials // BMC Psychiatry. – 2012. – Vol. 12. – P. 160.
47.    Datto C, Pottorf W.J., Feeley L., LaPorte S., Liss C. Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression // Ann Gen Psychiatry.–  2016. – Vol. 15. – P. 9. 
48.    Loebel A., Cucchiaro J., Silva R. et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study // Am J Psychiatry. – 2014. – Vol. 171. – P. 169–177.
49.    Pikalov A., Tohen M., Tsai J., Loebel A. Efficacy of lurasidone in bipolar depression: pooled results of two adjunctive studies with lithium or valproate // Bipolar Disord. – 2016. – Vol. 18. – P. 178.
50.    Srisurapanont M., Yatham L.N., Zis A.P. Treatment of acute bipolar depression: A review of the literature // Can J Psychiatry. – 1995. – No. 40. – P. 533–544.
51.    Donnelly E.F., Goodwin F.K., Waldman I.N., Murphy D.L. Prediction of antidepressant responses to lithium // Am J Psychiatry. – 1978. – Vol. 135. – P. 552–556.
52.    Baron M., Gershon E.S., Rudy V., Jonas W.Z., Buchsbaum M. Lithium-carbonate response in depression – prediction by unipolar bipolar illness, average-evoked response, catechol-o-methyl transferase, and family history // Arch Gen Psychiatry. – 1975. – Vol. 32. – P. 1107–1111.
53.    Selle V., Schalkwijk S., Vázquez G.H., Baldessarini R.J. Treatments for acute bipolar depression: meta-analyses of 
placebo-controlled, monotherapy trials of anticonvulsants, lithium, and second-generation antipsychotics // Pharmacopsychiatry. – 2014. – Vol. 47. – P. 43–52. 
54.    Geddes J.R., Calabrese J.R., Goodwin G.M. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomized trials // Br J Psychiatry. – 2009. – Vol. 194. – P. 4–9.
55.    Calabrese J.R., Bowden C.L., Sachs G.S. et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bi- polar I depression // J Clin Psychiatry. – 1999. – Vol. 60. – P. 79–88.
56.    Bond D.J., Lam R.W., Yatham L.N. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis // J Affect Disord. – 2010. – Vol. 124. – P. 228–234.
57.    Durgam S., Earley W., Lipschitz A. et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression // Am J Psychiatry. – 2016. – Vol. 173. – P. 271–281.
58.    Yatham L.N., Vieta E., Durgam S. et al. Efficacy of Cariprazine in Bipolar Depression: Post Hoc Band-Pass Analyses of 2 Randomized, Double-Blind, Placebo-Controlled Trials. – Atlanta, Georga: American Psychiatric Association Annual Meeting, 2016.
59.    Earley W., Burgess M., Rekeda L. et al. Cariprazine in treatment of bipolar disorder. Double blind. placebo-controlled phase 3 study // Am J Psychiatry. – 2019. – No. 176. – P. 439–448.
60.    McGirr A., Vohringer P.A., Ghaemi S.N., Lam R.W., Yatham L.N. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomized placebo-controlled trials // Lancet Psychiatry. – 2016. – Vol. 3. – P. 1138–1146.
61.    Tohen M., Vieta E., Calabrese J. et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression // Arch Gen Psychiatry. – 2003. – Vol. 60. – P. 1079–1088.
62.    Brown E.B., McElroy S.L., Keck P.E. Jr. et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression // J Clin Psychiatry. – 2006. – Vol. 67. – P. 1025–1033.
63.    Schoeyen H.K., Kessler U., Andreassen O.A. et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment // Am J Psychiatry. – 2015. – Vol. 172. – P. 41–51.
64.    McGirr A., Karmani S., Arsappa R. et al. Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression // World Psychiatry. – 2016. – Vol. 15. – P. 85–86.
65.    Tseng P.T., Chen Y.W., Tu K.Y. et al. Light therapy in the treatment of patients with bipolar depression: a meta-analytic study // Eur Neuropsychopharmacol. 2016. – Vol. 26. – P. 1037–1047.
66.    Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression // J Clin Psychiatry. – 2012. – Vol. 73. – P. 81–86.
67.    Grosso G., Pajak A., Marventano S. et al. Role of omega-3 fatty acids in the treatment of depressive     disorders: a comprehensive meta-analysis of randomized clinical trials // PLoS ONE. – 2014. – Vol. 9. – P. e96905.
68.    Rosenblat J.D., Kakar R., Berk M., et al. Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-analysis // Bipolar Disord. – 2016. – Vol. 18. – P. 89–101
69.    Bauer M., Berman S., Stamm T. et al. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study // Mol Psychiatry. – 2016. – Vol. 21. – P. 229–236.
70.    Mosolov S.N., Kostyukova E.G. Lechenie bol'nykh s rekurrentnym depressivnym rasstroistvom v Natsional'nom rukovodstve Psikhiatriya / pod red. Aleksandrovskii Yu.A., Neznanov N.G. / Geotar-Media, 2-e izdanie pererabotannoe // 2018, – s. 654–703.
71.    Mosolov S.N., Moshchevitin.S.Yu. Primenenie elektrosudorozhnoi terapii dlya obryva kontinual'nogo techeniya terapevticheski rezistentnykh affektivnogo i shizoaffektivnogo psikhozov // Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova. – 1990. – № 4. – S. 121–125.
72.    Young A.H., Calabrese J.R., Gustafsson U. et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies // Int J Bipolar Disord. – 2013. – Vol. 1. – P. 10.
73.    Calabrese J.R., Keck P.E., Macfadden W. et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression // Am J Psychiatry. – 2005. – Vol. 162. – P. 1351–1360.
74.    Thase M.E., Macfadden W., Weisler R.H. et al. Efficacy of quetiapine monotherapy in bipolar I and II depression – A double-blind, placebo-controlled study (The BOLDER II study) // J Clin Psychopharmacol. – 2006. – Vol. 26. – P. 600–609.
75.    Suppes T., Datto C., Minkwitz M., Nordenhem A., Walker C., Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression // J Affect Disord. – 2010. – Vol. 121. – P. 106–115.
76.    Young A.H., McElroy S.L., Bauer M. et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) // J Clin Psychiatry. – 2010. – Vol. 71. – P. 150–162. 
77.    Jeong J.H., Bahk W.M., Woo Y.S. et al. Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study // Neuropsychiatr Dis Treat. – 2013. – Vol. 9. – P. 197–204.
78.    Ahn Y.M., Nam J.Y., Culver J.L., Marsh W.K., Bonner J.C., Ketter T.A. Lamotrigine plus quetiapine combination therapy in treatment- resistant bipolar depression // Ann Clin Psychiatry. – 2011. – Vol. 23. – P. 17–24.
79.    Judd L.L., Akiskal H.S., Schettler P.J. et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder // Arch Gen Psychiatry. – 2003. – Vol. 60. – P. 261–269.
80.    Suppes T., Marangell L.B., Bernstein I.H. et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression // J Affect Disord. – 2008. – Vol. 111. – P. 334–343.
81.    Amsterdam J.D., Lorenzo-Luaces L., Soeller I., Li S.Q., Mao J.J., DeRubeis R.J. Short-term venlafaxine vs. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate // Br J Psychiatry. – 2016. – Vol. 208. – P. 359–365.
82.    Calabrese J.R., Huffman R.F., White R.L. et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials // Bipolar Disord. – 2008. – Vol. 10. – P. 323–333.
83.    Altshuler L.L., Sugar C.A., McElroy S.L. et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: A randomized double-blind comparison // Am J Psychiatry. – 2017. – Vol. 173. – P. 266–276.
84.    Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode // J Clin Psychopharmacol. – 1998. – Vol. 18. – P. 414–417.
85.    Amsterdam J.D., Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression // J Affect Disord. – 2000. – Vol. 59. – P. 225–229.
86.    Calabrese J.R., Bowden C.L., Sachs G. et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder // J Clin Psychiatry. – 2003. – Vol. 64. – P. 1013–1024.
87.    Sachs G.S. A 25-year-old woman with bipolar disorder // JAMA. – 2001. – Vol. 285. – P. 454–462.
88.    Muzina D.J., Gao K., Kemp D.E. et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo-controlled trial // J Clin Psychiatry. – 2011. – Vol. 72. – P. 813–819.
89.    Young L.T., Joffe R.T., Robb J.C., MacQueen G.M., Marriott M., Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression // Am J Psychiatry. – 2000. – Vol. 157. – P. 124–26.
90.    Winsberg M.E., DeGolia S.G., Strong C.M., Ketter T.A. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression // J Affect Disord. – 2001. – Vol. 67. – P. 207–212.
91.    Wang P.W., Nowakowska C., Chandler R.A., et al. Divalproex extended- release in acute bipolar II depression // J Affect Disord. – 2010. – Vol. 124. – P. 170–173.
92.    Amsterdam J.D., Shults J., Brunswick D.J., Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression – low manic switch rate // Bipolar Disord. – 2004. – Vol. 6. – P. 75–81. 
93.    Amsterdam J.D., Garcia-Espana F., Fawcett J. et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode // J ClinPsychopharmacol. – 1998. – Vol. 18. – P. 435–440.
94.    Amsterdam J.D., Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study // Am J Psychiatry. – 2010. – Vol. 167. – P. 792–800.
95.    Fornaro M., McCarthy M.J., De Berardis D. et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study // Neuropsychiatr Dis Treat. – 2013. – Vol. 9. – P. 243–251.
96.    Zimina S.V., Kostyukova E.G., Mosolov S.N. Dnevnaya dinamika vospriyatiya vremeni pri zatormozhennoi i trevozhnoi depressii u bol'nykh bipolyarnym rasstroistvom II tipa // Zhurn. psikhiatrii i nevrologii im. S.S. Korsakova. – 2016. – Tom 116. – vypusk 12. – s. 34-38.
97.    Mosolov S.N., Kostyukova E.G., Ushkalova A.V. Varianty farmakoterapii depressivnoi fazy bipolyarnogo affektivnogo rasstroistva tipa II // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. – 2015. – Tom 115. – №1 (vyp. 2).– s. 23-30.
98.    Magalhaes P.V., Dean O.M., Bush A.I. et al. N-acetyl cysteine add-on treatment for bipolar II disorder: A subgroup analysis of a randomized placebo-controlled trial // J Affect Disord. – 2011. – Vol. 129. – P. 317–320.
99.    Stamm T.J., Lewitzka U., Sauer C. et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study // J Clin Psychiatry. – 2014. – Vol. 75. – P. 162–168.
100.    Ahlfors U.G., Baastrup P.C., Dencker S.J. et al. Neuroleptic-induced extrapyramidal side effects in bipolar and schizophrenic patients // Acta Psychiatr. Scand. – 1981, Sep. – Vol. 64, No. 3. – P. 226–237.